Lutetium (177Lu) rhPSMA-10.1 injection

DRUG3 trials

Sponsors

Blue Earth Therapeutics Limited, Blue Earth Therapeutics Ltd

Conditions

Metastatic Castration-resistant Prostate CancerMetastatic castration-resistant prostate cancer (mCRPC)PSMA-positive non-curative metastatic castration-resistant prostate cancerProstate CancerProstatic DiseasesProstatic NeoplasmsUrogenital NeoplasmsmCRPC

Phase 1

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

RecruitingNCT05413850

Blue Earth Therapeutics LtdmCRPC, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer +3

Start: 2022-07-20End: 2028-03-31Target: 82Updated: 2026-03-02

An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with metastatic castrate-resistant prostate cancer

RecruitingCTIS2024-511537-35-00

Blue Earth Therapeutics LimitedMetastatic castration-resistant prostate cancer (mCRPC)

Start: 2024-02-09Target: 42Updated: 2025-11-13

A randomised, multi-centre, intra-patient imaging and dosimetry crossover study of lutetium (177Lu) rhPSMA-10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with non-curative metastatic prostate cancer

CompletedCTIS2024-515264-31-00

Blue Earth Therapeutics LimitedPSMA-positive non-curative metastatic castration-resistant prostate cancer

Start: 2025-04-15End: 2025-08-14Target: 18Updated: 2025-06-13

Related Papers

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies

EJNMMI Radiopharmacy and Chemistry2024-02-2611 citations

First Safety and Efficacy Data with the Radiohybrid<sup>177</sup>Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer

Journal of Nuclear Medicine2023-12-2112 citations